ClinVar Miner

Submissions for variant NM_000138.4(FBN1):c.6313+2T>C (rs1555395257)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000519359 SCV000618005 pathogenic not provided 2016-02-09 criteria provided, single submitter clinical testing Although the c.6313+2 T>C variant has not been reported as a pathogenic variant or as a benign variant to our knowledge, it destroys the canonical splice donor site in intron 51 and is predicted to cause abnormal gene splicing. The c.6313+2 T>C variant is predicted to result in in-frame skipping of exon 51 and the loss of one TGF-beta binding domain. Other splice site variants in the FBN1 gene resulting in skipping of exon 51 have been reported in the Human Gene Mutation Database in association with FBN1-related disorders (Stenson et al., 2014). Furthermore, the c.6313+2 T>C variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, c.6313+2 T>C in the FBN1 gene is interpreted as a pathogenic variant
Center for Medical Genetics Ghent,University of Ghent RCV000663861 SCV000787219 likely pathogenic Marfan syndrome 2017-11-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.